Search
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
GTB-3550
go.drugbank.com/drugs/DB18494InvestigationalGTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form
Flavin adenine dinucleotide
go.drugbank.com/drugs/DB03147ApprovedA condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g., D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinuc...
Docetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigationalDocetaxel binds to microtubules but does not interact with dimeric tubulin. … [L46466] Docetaxel was approved by the FDA in 1996 and is available in solution for injection for intravenous or parenteral administration.[A259676]
Mupirocin
go.drugbank.com/drugs/DB00410ApprovedInvestigationalVet approved[L10580] It primarily works by inhibiting bacterial protein synthesis. … _ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_.
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawnOn November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use in the US … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595Approved[L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Standard therapy involves cortisol replacement, but typically requires supraphysiological glucocorticoid doses to lower both ACTH and adrenal androgens, resulting in chronic glucocorticoid overexposure … Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory